Spero Licenses Innovent Anti-CD40L Antibody

Company: Spero Therapeutics / Innovent Biologics Event type: Licensing deal and strategic pipeline pivot Modality: Fc-silent monoclonal antibody Asset: SP001 / IBI355 Target: CD40L Disease area: IgG4-related disease; Sjogren’s disease in China Signal strength: 4 / 5 — Major immunology and cross-border platform signal Summary…